Last reviewed · How we verify
NCT04423406
The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy
trial in Carotid Artery Diseases in 150 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Zibo Central Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 August 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 27 February 2022 |
| Sites | 1 location across China |
Conditions studied
- Carotid Artery Diseases — all drugs for Carotid Artery Diseases →
Sponsor
Zibo Central Hospital
Who can join
Adults 18 to 85, any sex, with Carotid Artery Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
150 selected patients will be recruited, who have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard ultrasonography. For each of the plaques, standard ultrasonography will be used to evaluate lesion echogenicity, while contrast-enhanced ultrasonography (CEUS) will be used to perform the visual and quantitative analysis of neovascularization. Each technique will be applied at baseline (at the time of study enrollment) and following 0.5、1 year of Elococumab Injection treatment. During the study, these patients will be treated with Elococumab Injection (1ml:140mg),ih, every two weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study.
Chen J, Zhao F, Lei C, Qi T, et al · · 2022 · cited 10× · PMID 36686711 · DOI 10.3389/fphar.2022.999224
Verify or expand the search:
- PubMed search for NCT04423406
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carotid Artery Diseases
Currently open trials in the same condition.
- NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
- NCT06924593 — Study on the Trans-Carotid Artery Occlusion Shunt System · NA · recruiting
- NCT06653387 — A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When · NA · recruiting
- NCT06276374 — Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients · NA · recruiting
- NCT06959628 — Study on the Trans-Carotid Artery Occlusion Shunt System Combined With Introducer Sets · NA · recruiting
Other Zibo Central Hospital trials
Trials by the same sponsor.
- NCT07051564 — Clinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection · NA · recruiting
- NCT05802108 — Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering · Phase 4 · unknown
- NCT04416425 — Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04423406 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zibo Central Hospital
- Last refreshed: 21 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04423406.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing